Page 3 - Les Meilleurs doctors pour votre Thérapie ciblée - TOP 68 des médecins

Le Dr Alemdar est spécialisé en thérapie ciblée au Complexe hospitalier Medical Park Antalya, apportant des années d'expérience ciblée en oncologie.

• Certifié (Board-certified) en oncologie médicale par l'Université d'Akdeniz
• Formation approfondie en médecine interne et en oncologie
• A exercé dans des hôpitaux de premier plan, notamment l'hôpital universitaire d'Akdeniz
• Dédié aux approches personnalisées de traitement du cancer

Dr. Mariam Mohammed Hussein Abu Zeid is a clinical oncologist. She treats solid tumors and hematologic cancers. She earned her MBBCh from Ain Shams University in 2007 (Excellent). She completed a Master’s in Clinical Oncology and Nuclear Medicine in 2011 (Very Good). She received a Ph.D. in 2018 and an ESMO Certificate in 2015.

She leads and monitors clinical trials. Her work includes data collection and analysis. She administers chemotherapy and manages treatment toxicities. She also plans care with multidisciplinary teams. Her experience includes Ain Shams University Hospitals (2009–2012), the International Medical Center (2012–2014), and Wadi El Nile Hospital (2015–2019). Her roles covered diagnosis and staging, supportive care, quality improvement, and screening. She educates patients and families about the diagnosis, treatment options, and palliative care.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.

Dr. Nir Kleinmann, MD, directs the Endourology and Kidney Stones Unit at Sheba Medical Center. He is an expert in minimally invasive urology and urologic oncology. His focus is the kidney and upper urinary tract. He was named among Israel’s Best Doctors for 2025–2026 by Forbes and ResultMed.

He is a pioneer of kidney‑sparing laser surgery. He uses a dual‑laser system with neodymium and holmium for complex tumors. His expertise includes UTUC, kidney and prostate cancer, kidney stones, and BPH.

His research includes the OLYMPUS trial on chemoablation for UTUC. He has more than 60 publications.

He is an Israeli board‑certified urologist. He is a Fellow of the American Endourology Society and a member of the Israeli Urological Association and the EAU. He completed fellowships in Endourology and Minimally Invasive Surgery at Thomas Jefferson University. He also completed a fellowship in Kidney Cancer Research at McMaster University.

Directeur clinique de l'unité multidisciplinaire du sein aux Kliniken Essen-Mitte – Sherko Kuemmel dirige la recherche et le traitement avancés du cancer du sein.

• 322 publications évaluées par des pairs sur le cancer du sein
• Membre du conseil d'administration de l'AGO – élaboration des directives sur le cancer du sein
• Dirige des essais cliniques internationaux en tant qu'IP mondial
• Membre de la faculté de l'ESMO pour la formation sur le cancer du sein

Dr. Lucía González Cortijo is a medical oncologist with more than 20 years of experience. She has led the Medical Oncology Department at Hospital Universitario Quirónsalud Madrid since 2020. Her focus areas include breast and gynecologic cancers. She also works in precision oncology, targeted therapies, and immunotherapy.

She has been Principal Investigator in more than 20 Phase II–III clinical trials. She has also served as sub-investigator in over 50 international trials. She previously worked at Quirónsalud Madrid from 2009 to 2020. Before that, she was at MD Anderson Cancer Center Madrid from 2002 to 2009.

She holds an MD and a PhD (cum laude) from the Autonomous University of Madrid. She completed her Medical Oncology specialty training at Hospital 12 de Octubre. She also earned a Master’s in Molecular Oncology. She is a member of SEOM, ESMO, ASCO, and GEICAM. She is a university lecturer.

Spécialisé dans les procédures endoscopiques avancées, le Dr Erdogan apporte son expertise en CPRE (cholangiopancréatographie rétrograde endoscopique), écho-endoscopie (EUS) et traitement des MICI (Maladies Inflammatoires Chroniques de l'Intestin) à l'Hôpital Liv de l'Université İstinye Topkapı.

• Stage clinique (fellowship) en gastro-entérologie à l'Hôpital de la Ville d'Ankara
• A publié plusieurs articles de recherche sur le traitement des maladies inflammatoires de l'intestin
• Expérimenté en myotomie endoscopique par voie orale (POEM) et en dissection sous-muqueuse endoscopique (ESD)
• Contributeur actif à des revues à comité de lecture dans le domaine de la gastro-entérologie

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Eytan Aharon Ben‑Ami, MD, is a Senior Physician in the Sarcoma and Bone Oncology Service at Sheba Medical Center. He heads the Oncology Division and the Early-Phase Clinical Trials Unit. He founded the Sheba Clinical Research Organization. He is an academic affiliate at Tel Aviv University.

He specializes in sarcomas and primary bone tumors, including soft tissue sarcoma, liposarcoma, leiomyosarcoma, and osteosarcoma. He leads Phase I trials in targeted therapy and immunotherapy. He designs personalized treatment plans for rare cancers. He also develops patient-centered programs, including pilots in advanced immunotherapy delivery.

He completed a fellowship in Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute/Harvard Cancer Center. He has authored more than 40 publications on early detection, molecular and viral mechanisms, and new cancer therapies.

Dr. Yaacov Lawrence, MA, MBBS, MRCP, is Chair of Radiation Oncology at Sheba Medical Center. He has nearly 30 years of experience in precision radiation oncology and neuro-oncology.

He is an expert in advanced radiation therapy and radiosurgery. He performs stereotactic radiosurgery for brain tumors. He leads Sheba’s GI Cancer Program in gastrointestinal oncology. He also provides precision care for lung and prostate cancers. He pioneered celiac plexus radiosurgery for severe pain from pancreatic cancer.

Training and credentials: MA and MBBS (Cambridge and UCLH); MRCP (RCP); Radiation Oncology fellowship (Thomas Jefferson University). Honors include the ASCO Young Investigator Award and Fellow of ASTRO (FASTRO). He has authored over 280 publications. He is Director of the Center for Translational Radiation Oncology and an Associate Professor at Tel Aviv University.

Dr. Emad Shash, M.B.B.Ch, MSc, M.D., is a medical oncologist. He is the Medical Director of the Breast Comprehensive Cancer Hospital at NCI. He leads the Medical Oncology Department and is the Breast Program Director at Shifaa Al Orman Cancer Hospital in Luxor. His clinical focus includes breast, gynecologic, genitourinary, thoracic, gastrointestinal, and rare cancers. He specializes in systemic therapy, including chemotherapy, targeted therapy, and immunotherapy.

He served as coordinating research physician and medical lead at the EORTC from 2011 to 2015. Since 2008, he has contributed to more than 70 international oncology trials as a coordinator, sub-investigator, principal investigator, and sponsor medical monitor. Credentials include M.B.B.Ch (2004), MSc (2010), MD (2015), and the EORTC Certificate of Excellence (2015). He also holds a Diploma in Hospital Quality Management & Patient Safety (JCI/57357, 2017). He is a Fellow of the EIO. He is a member of ESMO (panel voting), ESGO, and ASCO (IAC), and serves on the ECRIN board.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Médecin-chef du Centre d'oncologie de l'Assuta Medical Center – expert de premier plan en thérapie ciblée.

• Se spécialise dans les traitements d'oncologie de précision
• Vaste expérience des thérapies anticancéreuses personnalisées
• Exerce dans l'un des meilleurs centres anticancéreux d'Israël

Le Dr Shaikh est spécialisé dans les chirurgies du cancer de la bouche, avec un accent mis sur la préservation des organes et la réadaptation fonctionnelle, au HCG Manavata Cancer Centre.

• 3 ans d'expérience en oncologie chirurgicale
• Formation post-doctorale en oncologie chirurgicale de la tête et du cou
• Compétent dans les chirurgies maxillofaciales et de la tête et du cou majeures
• Chercheur avec de multiples publications

Le Dr Raj Nagarkar a pratiqué plus de 50 000 chirurgies oncologiques et dirigé plus de 200 essais cliniques, se concentrant sur l'oncologie chirurgicale mammaire et thoracique.

• Formé au Tata Memorial Hospital et au Royal College of Surgeons d'Édimbourg
• Spécialisé en oncologie chirurgicale mammaire et thoracique
• Professeur pour le DNB Superspecialty Surgical Oncology
• 19 ans d'expérience en oncologie chirurgicale
• Nombreuses publications internationales et nationales

Le Dr Lalit a pratiqué avec succès plus de 10 000 interventions chirurgicales majeures, en se concentrant sur les chirurgies oncologiques mini-invasives au HCG Manavata Cancer Centre.

• Plus de 10 ans d'expérience en oncologie chirurgicale
• Fellowship au Tata Medical Centre avec une spécialité en cancer gastro-intestinal
• Professeur adjoint au State Cancer Institute et au Government Cancer Hospital
• Nombreuses publications nationales et internationales
• Approche éthique et centrée sur le patient

Le Dr Joan Albanell Mestres dirige le programme de cancer du sein de HM Delfos et a publié plus de 120 articles avec plus de 9 000 citations.

• MBBS (Diplôme de médecine) de l'Université Autónoma de Barcelona
• Résidence à la clinique Vall d'Hebron
• Recherche menée sur la télomérase à New York
• Directeur de la recherche sur le cancer à Del Mar
• Membre éminent de GEICAM, CIBERONC, AIECA, SEOM